Jaguar Health, Inc.(JAGX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $12.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
JAGX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Jaguar Health, Inc. (JAGX), a Healthcare sector company. JAGX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $12.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Jaguar Health, Inc. reports quarterly revenue of $20.3M, net income of $8.7M, free cash flow of $8.8M. Top institutional holders of JAGX by reported 13-F value include UBS Group AG, GEODE CAPITAL MANAGEMENT,, TWO SIGMA SECURITIES,, based on the most recent SEC filings. JAGX trades on the Nasdaq exchange and files with the SEC under CIK 1585608. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JAGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Jaguar Health, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$20.3M
Net Income
Q1 2026
$8.7M
Free Cash Flow
Q1 2026
$8.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+17.9% YoYNet Income
-28.9% YoYOperating Income
-33.9% YoYEPS (Diluted)
+99.1% YoYTotal Assets
-24.5% YoYOp. Cash Flow
+28.7% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $11.5M +17.9% | $9.8M -18.4% | $12.0M +175.8% | $4.3M -24.9% | $5.8M +30.8% | $4.4M |
| Net Income | $-54.0K -28.9% | $-41.9K +99.9% | $-47.5M -90116.7% | $-52.6K +99.9% | $-38.5M -19.9% | $-32.1M |
| Operating Income | $-45.9M -33.9% | $-34.3M +0.4% | $-34.4M +15.5% | $-40.7M -40.6% | $-28.9M +6.1% | $-30.8M |
| EPS (Diluted) | $-22.97 +99.1% | $-2678.17 -7302.3% | $-36.18 +59.0% | $-88.22 | — | — |
| Total Assets | $38.3M -24.5% | $50.8M +7.0% | $47.5M -10.9% | $53.3M +46.3% | $36.4M -11.3% | $41.0M |
| Operating Cash Flow | $-23.7M +28.7% | $-33.2M -0.4% | $-33.1M +5.3% | $-35.0M -70.9% | $-20.5M +10.0% | $-22.7M |
AI Insight: JAGX Ratio Trends
Operating margin swung 139pp from -89% TTM to +50.2% in Q1 2026, but underlying profitability remains severely impaired.
• Operating margin rebounded to +50.2% in Q1 2026 from -89.0% TTM, a dramatic 139pp swing suggesting operational restructuring or one-time gains.
• ROA deteriorated consistently through 2025, declining from -61.8% in Q2 2024 to -86.2% in Q2 2025, indicating worsening asset productivity.
⚠ Q1 2026 margin turnaround lacks supporting profitability metrics (ROE/ROA/ROIC absent); verify if rebound is sustainable or driven by non-recurring items.
⚠ Sparse financial disclosures across most ratios suggest potential data quality or reporting issues requiring clarification.
Get alerted when JAGX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Jaguar Health, Inc. including:
Top Institutional Holders of JAGX
UBS Group AG
$41.8K112,906 shGEODE CAPITAL MANAGEMENT, LLC
$40.8K110,129 shTWO SIGMA SECURITIES, LLC
$4.7K12,551 shSBI Securities Co., Ltd.
$953.002,571 shTower Research Capital LLC (TRC)
$856.002,311 shWELLS FARGO & COMPANY/MN
$74.00200 shLeonteq Securities AG
$70.00188 shINTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC
$18.0045 shHRT FINANCIAL LP
$5.0015,187 shBlackRock, Inc.
$1.004 sh
| Fund | Value | Shares |
|---|---|---|
| UBS Group AG | $41.8K | 112,906 |
| GEODE CAPITAL MANAGEMENT, LLC | $40.8K | 110,129 |
| TWO SIGMA SECURITIES, LLC | $4.7K | 12,551 |
| SBI Securities Co., Ltd. | $953.00 | 2,571 |
| Tower Research Capital LLC (TRC) | $856.00 | 2,311 |
| WELLS FARGO & COMPANY/MN | $74.00 | 200 |
| Leonteq Securities AG | $70.00 | 188 |
| INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | $18.00 | 45 |
| HRT FINANCIAL LP | $5.00 | 15,187 |
| BlackRock, Inc. | $1.00 | 4 |
More Healthcare Companies
View all Healthcare →Put JAGX on your watchlist
Track score changes the day Jaguar Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is JAGX a good stock to buy?
13F Pro's AI-powered analysis of Jaguar Health, Inc. (JAGX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for JAGX are available on the JAGX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own JAGX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling JAGX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Jaguar Health, Inc.'s investment landscape.